Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Astrazeneca
Press release submission
| Sep 16, 2018
ASTRAZENECA: US FDA approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukemia
Marian Johns
| Jan 17, 2018
FDA approves Lynparza as first PARP Inhibitor for treating metastatic breast cancer
Trending
+
Pharmaceuticals
Patient Daily
| Apr 24, 2024
Researchers Look for Long-Term Hearing Loss Treatments
+
Pharmaceuticals
Patient Daily
| Apr 25, 2024
"My Future Depends on It:" Local Teacher Raises Nearly $95,000 for Lung Cancer Research
+
Pharmaceuticals
Patient Daily
| Apr 25, 2024
Labor and delivery nurse overcomes cancer and heart failure
+
Pharmaceuticals
Patient Daily
| Apr 24, 2024
American Lung Association Report: Utah Receives Poor Grades for Ozone and Particle Pollution